

# Sarah C Markt, Scd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8556762/publications.pdf>

Version: 2024-02-01

83  
papers

1,329  
citations

279798

23  
h-index

395702

33  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1361-1370.	1.8	79
2	Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men. <i>European Urology</i> , 2015, 67, 191-194.	1.9	74
3	Sex differences in the associations of obstructive sleep apnoea with epidemiological factors. <i>European Respiratory Journal</i> , 2018, 51, 1702421.	6.7	72
4	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 851-860.	4.7	65
5	Incidence of Kidney Stones in the United States: The Continuous National Health and Nutrition Examination Survey. <i>Journal of Urology</i> , 2022, 207, 851-856.	0.4	55
6	Family History of Breast or Prostate Cancer and Prostate Cancer Risk. <i>Clinical Cancer Research</i> , 2018, 24, 5910-5917.	7.0	52
7	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. <i>Cancer</i> , 2016, 122, 3127-3135.	4.1	46
8	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 ( <i>CHEK2</i> ) With Susceptibility to Testicular Germ Cell Tumors. <i>JAMA Oncology</i> , 2019, 5, 514.	7.1	43
9	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019, 75, 399-407.	1.9	43
10	Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 302-308.	2.5	41
11	Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. <i>PLoS ONE</i> , 2018, 13, e0193047.	2.5	41
12	Circadian clock genes and risk of fatal prostate cancer. <i>Cancer Causes and Control</i> , 2015, 26, 25-33.	1.8	39
13	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. <i>PLoS ONE</i> , 2013, 8, e53067.	2.5	39
14	5 $\alpha$ -Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1301.	5.1	38
15	Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. <i>Journal of the National Cancer Institute</i> , 2021, 113, 727-734.	6.3	36
16	Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort. <i>Sleep</i> , 2015, 38, 1405-1410.	1.1	35
17	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1086-1093.	7.0	35
18	Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1049-1058.	1.8	30

#	ARTICLE	IF	CITATIONS
19	Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. <i>International Journal of Cancer</i> , 2017, 141, 1794-1802.	5.1	28
20	Weight Loss as an Untapped Early Detection Marker in Pancreatic and Periampullary Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6283-6292.	1.5	28
21	Snus use, smoking and survival among prostate cancer patients. <i>International Journal of Cancer</i> , 2016, 139, 2753-2759.	5.1	27
22	Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. <i>Journal of Biological Rhythms</i> , 2016, 31, 461-469.	2.6	26
23	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. <i>European Urology</i> , 2019, 76, 33-40.	1.9	26
24	Association between <i>Trichomonas vaginalis</i> and prostate cancer mortality. <i>International Journal of Cancer</i> , 2019, 144, 2377-2380.	5.1	21
25	A Walking Intervention Among Men With Prostate Cancer: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1021-e1028.	1.9	20
26	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , 2018, 73, 262-270.	1.9	20
27	Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy. <i>Surgery</i> , 2021, 170, 207-214.	1.9	19
28	Height, Obesity, and the Risk of <i>TMPRSS2:ERG</i> -Defined Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 193-200.	2.5	18
29	Midlife metabolic factors and prostate cancer risk in later life. <i>International Journal of Cancer</i> , 2018, 142, 1166-1173.	5.1	18
30	Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort. <i>Cancer Prevention Research</i> , 2018, 11, 621-628.	1.5	15
31	Genetic variation across C-reactive protein and risk of prostate cancer. <i>Prostate</i> , 2014, 74, 1034-1042.	2.3	14
32	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). <i>Prostate</i> , 2015, 75, 1677-1681.	2.3	14
33	Sniffing out significant $p$ values: genome wide association study of asparagus anosmia. <i>BMJ, The</i> , 2016, 355, i6071.	6.0	11
34	Age $\geq 40$ Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. <i>European Urology Focus</i> , 2017, 3, 621-628.	3.1	10
35	The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses' Health Study and Nurses' Health Study II. <i>International Journal of Epidemiology</i> , 2020, 49, 599-607.	1.9	10
36	A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. <i>Surgery</i> , 2022, 172, 257-264.	1.9	9

#	ARTICLE	IF	CITATIONS
37	Excess cancer prevalence in men with HIV: A nationwide analysis of Medicaid data. <i>Cancer</i> , 2022, 128, 1987-1995.	4.1	9
38	Smoking cessation among men following cancer diagnosis: a matched cohort study. <i>Journal of Cancer Survivorship</i> , 2018, 12, 786-793.	2.9	8
39	Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial. <i>Prostate</i> , 2020, 80, 1304-1313.	2.3	8
40	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 58-64.e1.	1.9	7
41	Association Between Operative Approach and Venous Thromboembolism Rate Following Hepatectomy: a Propensity-Matched Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2778-2787.	1.7	7
42	Prostate Cancer Screening and Young Black Men: Can Early Communication Avoid Later Health Disparities?. <i>Journal of Cancer Education</i> , 2022, 37, 1460-1465.	1.3	6
43	Weight Tracking as a Novel Prognostic Marker After Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 3450-3459.	1.5	6
44	Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 982-990.	2.5	6
45	Baldness and Risk of Prostate Cancer in the Health Professionals Follow-up Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1229-1236.	2.5	5
46	Female Authorship Trends in Urology During the COVID-19 Pandemic. <i>European Urology</i> , 2021, 79, 322-324.	1.9	5
47	Reassessing the role of surgery in the elderly or chronically sick with proximal extrahepatic cholangiocarcinoma. <i>Surgery</i> , 2021, 169, 233-239.	1.9	5
48	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 683-693.	2.3	5
49	Patient-centered Weight Tracking as an Early Cancer Detection Strategy. <i>Journal of Cancer Prevention</i> , 2020, 25, 181-188.	2.0	5
50	Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 78-84.	1.9	4
51	Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 284-291.	3.9	4
52	Gender Disparities in Bladder Cancer-Specific Survival in High Poverty Areas Utilizing Ohio Cancer Incidence Surveillance System (OCISS). <i>Urology</i> , 2021, 151, 163-168.	1.0	4
53	Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. <i>American Journal of Surgery</i> , 2022, 223, 927-932.	1.8	4
54	The Impact of Race and Sex on Metastatic Bladder Cancer Survival. <i>Urology</i> , 2022, 165, 98-105.	1.0	4

#	ARTICLE	IF	CITATIONS
55	“Robotic fatigue” The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 365.e17-365.e23.	1.6	3
56	Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk. <i>Prostate</i> , 2021, 81, 487-496.	2.3	3
57	Three Fold Risk of Atrial Fibrillation in Ibrutinib Treated CLL Patients without Increased Risk of Stroke: A SEER-Medicare Database Analysis. <i>Blood</i> , 2020, 136, 18-19.	1.4	3
58	Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 1850-1859.	2.8	3
59	Body Mass Index and Outcomes in Germ-Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 283-290.	1.9	2
60	Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. <i>Journal of Pancreatic Cancer</i> , 2021, 7, 31-38.	0.9	2
61	Data Matching to Support Analysis of Cancer Epidemiology Among Veterans Compared With Non-Veteran Populations—An Exemplar in Brain Tumors. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 985-994.	2.1	2
62	ASO Visual Abstract: Weight Tracking as a Novel Prognostic Marker After Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 3462-3462.	1.5	2
63	Characterization and functional analysis of microbiome in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 541-541.	1.6	2
64	Evaluating Factors Associated With Continuous Glucose Monitoring Utilization With the Type 1 Diabetes Exchange Registry. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1580-1589.	2.2	2
65	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 783-789.	2.5	1
66	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262–70. <i>European Urology</i> , 2018, 73, e100-e101.	1.9	1
67	ASO Author Reflections: Prediagnosis Weight Loss: Early Detection and Postoperative Prognosis Among Patients with Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6293-6293.	1.5	1
68	Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. <i>Hpb</i> , 2022, 24, 925-932.	0.3	1
69	ASO Author Reflection: Post-pancreatectomy Weight Trends Predict Recurrence and Survival. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	1
70	Urinary 6-sulfatoxymelatonin Levels and Prostate Cancer Risk among Men in the Multiethnic Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 688-691.	2.5	1
71	CHALLENGE Trial 1 Year Feasibility Results—Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1277-1277.	2.5	0
72	Authors'™ reply to Rishniw. <i>BMJ: British Medical Journal</i> , 2017, 357, j2910.	2.3	0

#	ARTICLE	IF	CITATIONS
73	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermannsâ€™™ Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262â€™™70.. European Urology, 2018, 73, e96-e97.	1.9	0
74	Unintentional Weight Loss as a Marker of Malignancy Across Body Weight Categories. Current Cardiovascular Risk Reports, 2021, 15, 1.	2.0	0
75	Abstract 863: Circadian gene expression in metastatic sites and association with survival in metastatic castration-resistant prostate cancer. , 2021, , .		0
76	Circadian dysrhythm and advanced prostate cancer.. Journal of Clinical Oncology, 2014, 32, 199-199.	1.6	0
77	Association of age 40 and older with adverse outcome in metastatic testicular cancer (TC).. Journal of Clinical Oncology, 2015, 33, 386-386.	1.6	0
78	BMI at diagnosis and adverse outcomes among men with malignant testicular germ cell tumors.. Journal of Clinical Oncology, 2015, 33, 400-400.	1.6	0
79	Sunlight and testicular germ cell tumor rates in the USA.. Journal of Clinical Oncology, 2015, 33, e15565-e15565.	1.6	0
80	Melanoma risk in men with testicular germ cell tumors in the United States.. Journal of Clinical Oncology, 2015, 33, e15554-e15554.	1.6	0
81	Post-orchietomy adjuvant therapy versus surveillance for stage IS testicular cancer.. Journal of Clinical Oncology, 2017, 35, 406-406.	1.6	0
82	Finding a Place for Family History To Inform High-grade Prostate Cancer Risk. European Urology, 2022, , .	1.9	0
83	Characterization of fungal mycobiome in bladder cancer.. Journal of Clinical Oncology, 2022, 40, 542-542.	1.6	0